Skip to main content
. Author manuscript; available in PMC: 2019 Apr 12.
Published in final edited form as: Int J Pharm. 2017 Nov 21;538(1-2):48–56. doi: 10.1016/j.ijpharm.2017.11.037

Fig. 4.

Fig. 4.

a)In vivo /in vitro release for PLGA 503H + 20% 4HPR + 15% MgCO3 + 20% NaDC (baseline) and specialized excipients including 5% B-CD, 1% HPMC K4M, and 1% PVP K30. b) Implant erosion, and c) implant water uptake in vivo. (mean ± SE, n = 3).